Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects.
about
One single dose of etomidate negatively influences adrenocortical performance for at least 24h in children with meningococcal sepsisThe Treatment of Cushing's Disease.Role of "old" pharmacological agents in the treatment of Cushing's syndromeUpdates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapiesUpdate on medical treatment for Cushing's disease.Analogues of etomidate: modifications around etomidate's chiral carbon and the impact on in vitro and in vivo pharmacologyNew mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line.11β-Hydroxylase inhibitors protect against seizures in mice by increasing endogenous neurosteroid synthesis.Clinical and molecular pharmacology of etomidate.Etomidate and Ketamine: Residual Motor and Adrenal Dysfunction that Persist beyond Recovery from Loss of Righting Reflex in RatsEffects of Etomidate on the Steroidogenesis of Rat Immature Leydig Cells.Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice GuidelineMedical management of Cushing's disease: what is the future?Closed-loop continuous infusions of etomidate and etomidate analogs in rats: a comparative study of dosing and the impact on adrenocortical functionSteroidogenesis in the adrenal dysfunction of critical illness: impact of etomidateEctopic ACTH Production Leading to Diagnosis of Underlying Medullary Thyroid Carcinoma.Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.Drugs in the medical treatment of Cushing's syndrome.Management of Cushing disease.Adrenocortical carcinoma: a clinician's update.Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate.Recent developments in drug therapy for Cushing's disease.Medical management of Cushing's disease.Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.Cushing's syndrome: an update on current pharmacotherapy and future directions.Therapeutic Strategies for the Treatment of Severe Cushing's Syndrome.Management of hormone-secreting pituitary adenomas.Etomidate use for Cushing's syndrome caused by an ectopic adrenocorticotropic hormone-producing tumor.Treatment of severe psychosis due to ectopic Cushing's syndrome.Dimethoxy-etomidate: A Non-hypnotic Etomidate Analog that Potently Inhibits Steroidogenesis.Leukemia inhibitory factor stimulates steroidogenesis of rat immature Leydig cells via increasing the expression of steroidogenic acute regulatory protein.Adrenocortical carcinoma
P2860
Q24642816-96B74A9D-B9A3-455C-AD8A-45107A7884F7Q27010590-0C2FB457-A7A9-49FE-9908-19C08146561FQ28067685-58DFD72D-4217-40EC-8B8C-31C8D67ED9C8Q28076013-2B36B328-866E-4589-A414-DFB734E8A760Q33802284-7BFB5897-F120-4CBF-B3A8-EDA1FDD7DE7DQ34001757-6D6917CE-DED5-4301-B170-BF7F8BADDB08Q34204059-2C7C1797-530F-4CCE-8B66-D39FCDF5E03EQ35016917-3BE2FD49-9BB1-473D-8156-43A9B17DF667Q35024852-C8475C62-5888-4E67-921E-48611B4D8D9EQ35536303-4E4D99A6-11E2-44DD-8470-9D21E75AE6B4Q35837537-E8D97CB6-2529-41B6-AAEE-022E51383F91Q35916555-B4DE2C01-F369-4CC4-A8D9-B3F37C592104Q36236884-66952621-0D04-4E28-B1A4-8EAAB1E80105Q36501060-637BA347-FB25-4C71-92ED-F0D2D6D01C93Q36633846-9AB97CA3-99FC-4FB6-B14F-9753A5396DD5Q36815669-12FC711A-824B-4DB5-9F1D-ED3F1685178EQ37369828-49642F84-C807-402D-89ED-CDED98A5F30DQ37638759-484AE8C7-E768-4030-B152-A7E3907DD119Q37837501-A4117D7B-DE80-441E-BACD-D89A9B98ED5FQ37850996-0029FB30-F591-4BD5-B950-6DF3BC6E02DCQ37873797-00BF1339-5E5A-4026-B32A-B6774E69C849Q38112082-99E80ADC-C587-4126-8BD7-320AFA721D56Q38154515-C908FFEB-ACF9-4BF7-9010-3539011532E6Q38307934-1923B321-E1D7-4DF6-A592-FEA4DF64002CQ38541695-E06761C5-703F-4261-87B4-6407FEDF9A8BQ38718807-55CF3254-A114-4CF4-B263-0FD4BFBC1C0DQ39168432-1638E3B4-20D6-44DF-8B3E-5D38DAB2D1B2Q40460505-8F3B530B-A679-4882-BA9C-32BBD9256A93Q46906995-AA0AA86D-CBF9-4785-BE54-F3F4F3FE401CQ47224599-42B1A4C5-2074-43DD-8BCC-7DDB4335594BQ51374969-9D318569-C4D9-4518-8F0C-DB1399C90487Q57645859-A0D1E222-BD52-4A32-A62A-256181C805CD
P2860
Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
Infusion of low dose etomidate ...... lationship in normal subjects.
@en
Infusion of low dose etomidate ...... lationship in normal subjects.
@nl
type
label
Infusion of low dose etomidate ...... lationship in normal subjects.
@en
Infusion of low dose etomidate ...... lationship in normal subjects.
@nl
prefLabel
Infusion of low dose etomidate ...... lationship in normal subjects.
@en
Infusion of low dose etomidate ...... lationship in normal subjects.
@nl
P2093
P356
P1476
Infusion of low dose etomidate ...... lationship in normal subjects.
@en
P2093
P304
P356
10.1210/JCEM-70-5-1426
P407
P577
1990-05-01T00:00:00Z